Faruqi and Faruqui, LLP Logo
Share this page

Cempra, Inc. (CEMP)



Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Cempra, Inc. To Contact The Firm Before Lead Plaintiff Deadline

Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Cempra, Inc. (“Cempra” or the “Company”) (NASDAQ:CEMP) of the January 3, 2017 deadline to seek the role of lead plaintiff in a federal securities class action lawsuit filed against the Company and certain officers.

The lawsuit has been filed in the U.S. District Court for the Middle District of North Carolina on behalf of all those who purchased Cempra common stock between October 22, 2015 and November 1, 2016 (the “Class Period”).  The case, PASQUAL v. CEMPRA, INC. et al, No. 1:16-cv-01356 was filed on November 22, 2016, and has been assigned to Judge Thomas D. Schroeder.

The lawsuit focuses on whether the Company and its executives violated federal securities laws by failing to disclose that its lead product candidate, solithromycin, a pneumonia therapy drug, can cause an elevation in liver enzyme levels, a significant safety signal for hepatotoxicity.

Specifically, on November 2, 2016, the United States Food and Drug Administration (“FDA”) posted on its website a preliminary review of solithromycin in which it indicated that the drug can lead to an elevation in liver enzyme levels and other potential causes of hepatotoxicity. This came as a surprise as the Company had provided fully positive reviews of the development of solithromycin.

After the announcement, Cempra’s share price fell from $18.65 per share on November 1, 2016 to a closing price of $7.30 on November 2, 2016—an $11.35 or a 60.9% drop.

Take Action

If you invested in Cempra common stock or options between October 22, 2015 and November 1, 2016 and would like to discuss your legal rights, please fill out the form below. You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to rgonnello@faruqilaw.com.  Faruqi & Faruqi, LLP also encourages anyone with information regarding Cempra’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

Request Information

Please tell us about yourself by completing the form and we will provide you with additional
information on how to join the Class Action at no cost to you.

  • Case:
    Cempra, Inc. (CEMP)

* The submission of this form does not create an attorney-client relationship.

Contact Counsel

Richard W. Gonnello
Faruqi & Faruqi, LLP
685 Third Avenue 26th Floor
New York, NY 10017
Tel: (212) 983-9330


Case Details


  • 11/08/2016

Class Period:

  • 10/22/2015 - 11/01/2016

Send Information

If you have information regarding this case that you would like to make available, please click here to contact us about our investigation.